HOUSE_OVERSIGHT_024030.jpg
2.32 MB
Extraction Summary
1
People
8
Organizations
1
Locations
4
Events
1
Relationships
3
Quotes
Document Information
Type:
Financial report / investment portfolio review
File Size:
2.32 MB
Summary
This document is a confidential financial report page detailing the performance of two funds, New Leaf Ventures I (NLV-I) and New Leaf Ventures II (NLV-II), as of March 31, 2014. It highlights that both funds are performing in the top quartile according to Cambridge Associates and outlines their capital commitments ($310M and $450M respectively), Internal Rates of Return (IRR), and outperformance against major public indices like the S&P 500. The document bears a House Oversight stamp, suggesting it was obtained during a congressional investigation, likely regarding entities holding these investments.
People (1)
| Name | Role | Context |
|---|---|---|
| Fund Managers | Management |
Managers of New Leaf Funds (NLV-I and NLV-II)
|
Organizations (8)
| Name | Type | Context |
|---|---|---|
| New Leaf Funds |
Subject of the financial report (comprised of NLV-I and NLV-II)
|
|
| New Leaf Ventures I, L.P. |
Specific entity listed in performance table
|
|
| New Leaf Ventures II, L.P. |
Specific entity listed in performance table
|
|
| Cambridge Associates |
Provided tracking data placing NLV funds in the top quartile
|
|
| S&P |
Used for performance comparison (S&P 500, S&P Healthcare)
|
|
| NASDAQ |
Used for performance comparison (NASDAQ Composite)
|
|
| Russell |
Used for performance comparison (Russell 3000)
|
|
| House Oversight Committee |
Implied by Bates stamp 'HOUSE_OVERSIGHT'
|
Timeline (4 events)
Locations (1)
| Location | Context |
|---|---|
|
Market for healthcare venture capital mentioned in comparison data
|
Relationships (1)
Text refers repeatedly to 'Fund Managers' managing the NLV portfolios.
Key Quotes (3)
"NLV-I is in the top quartile of funds tracked by Cambridge Associates for U.S. healthcare venture capital in the 2005 vintage year."Source
HOUSE_OVERSIGHT_024030.jpg
Quote #1
"NLV-II’s current performance places the fund in the top quartile of funds tracked by Cambridge Associates for U.S. venture capital in the 2008 vintage year."Source
HOUSE_OVERSIGHT_024030.jpg
Quote #2
"The Fund Managers believe that NLV-II has unusually positive liquidity characteristics for a life sciences focused venture capital fund of its age"Source
HOUSE_OVERSIGHT_024030.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document